Programmed death-ligand 1 (PD-L1) is widely implicated in tumor immune evasion, and PD-L1 expression in tumor tissues has been reported to be associated with the responses to the current immune checkpoint therapy of melanoma and NSCLC [164,165,166,167,168]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.